Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option
As on 03 Apr 2025

Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option
EquityNAV
₹ 538.10
CAGR (3 Years)
19.01%
AUM (Cr)
₹ 7,637.04
Risk
Very High Risk
About Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option
The primary investment objective of the Scheme is to generate consistent returns by investing in equity / equity related or fixed income securities of Pharma and other associated companies
Breakdown of this Fund
Debt Others
2.47%
Healthcare
36.49%
Pharmaceuticals
113.78%
Retail
6.55%
Market Capitalization
Expense Ratio, Exit Load and Tax
Expense Ratio
1.12
Exit Load
1% if redeemed or switchd out on or before completion of 1 Months from the date ...
Stamp Duty
0.005% (from July 1st, 2020)
Tax Implication
Returns are taxed at 20%, if you redeem before one year. After 1 year, you are required to pay LTCG tax of 12.5% on returns of Rs 1.25 lakh+ in a financial year.